AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Precision Radiation Oncology Article
Article Link
Cite
EndNote(RIS) BibTeX
Collect
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

Radiotherapy of early-stage breast cancer

Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland, USA
Xcision Medical Systems, Columbia, Maryland, USA
Show Author Information

Abstract

Breast cancer is the most prevalent disease for women. With advances in breast cancer screening, most breast cancers are now diagnosed in the early stages. With knowledge of different subtypes and their behavior, breast cancer treatment has become more individualized. Radiation therapy as one of the mainstays of breast cancer treatment has also been evolving. This review attempts to provide a summary of the most influential clinical studies that have driven the technological advances in radiation therapy for early-stage breast cancer.

Keywords

radiation therapyearly-stage breast cancerpartial breast irradiationpreoperative RTwhole-breast irradiation

References

1

Fisher B, Bauer M, Margolese R, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med. 1985;312(11):665-673.
Crossref Google Scholar
2

Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087-2106.
Crossref Google Scholar
3

Punglia RS, Morrow M, Winer EP, Harris JR. Local therapy and survival in breast cancer. N Engl J Med. 2007;356(23):2399-2405.
Crossref Google Scholar
4

Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v8-v30.
Crossref Google Scholar
5

Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov. 2003;2(3):205-213.
Crossref Google Scholar
6

Jordan VC. Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. Br J Pharmacol. 2006;147(Suppl 1):S269-S276.
Crossref Google Scholar
7

Fisher B, Bryant J, Dignam JJ, et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol. 2002;20: 4141-4149.
Crossref Google Scholar
8

Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31(19):2382-2387.
Crossref Google Scholar
9

Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM. PRIME II investigators. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II):a randomised controlled trial [published correction appears in Lancet Oncol. 2015 Mar; 16(3):e105]. Lancet Oncol. 2015;16(3):266-273.
Crossref Google Scholar
10
San Antonio Breast Cancer Symposium®: 2021 SABCS® https://www.sabcs.org/2021-SABCS
11

Yarnold J, Ashton A, Bliss J, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol. 2005;75(1):9-17.
Crossref Google Scholar
12

Hopwood P, Haviland JS, Sumo G, et al. Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5-year follow-up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncol. 2010;11(3):231-240.
Crossref Google Scholar
13

START Trialists' Group, Bentzen SM, Agrawal RK, et al. The UK standardisation of breast radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008;9(4):331-341.
Crossref Google Scholar
14

START Trialists' Group, Bentzen SM, Agrawal RK, et al, The UK standardisation of breast radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371(9618):1098-1107.
Crossref Google Scholar
15

Whelan T, MacKenzie R, Julian J, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst. 2002;94(15):1143-1150.
Crossref Google Scholar
16

Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6):513-520.
Crossref Google Scholar
17

Wang SL, Fang H, Song YW, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2019;20(3):352-360.
Crossref Google Scholar
18

Offersen BV, Alsner J, Nielsen HM, et al. Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase III trial: the DBCG HYPO trial. J Clin Oncol. 2020;38(31):3615-3625.
Crossref Google Scholar
19

FAST Trialists group, Agrawal RK, Alhasso A, Barrett-Lee PJ, et al. First results of the randomised UK FAST trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015). Radiother Oncol. 2011;100(1):93-100.
Crossref Google Scholar
20

Brunt AM, Haviland JS, Sydenham M, et al. Ten-year results of FAST: a randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer. J Clin Oncol. 2020;38(28):3261-3272.
Crossref Google Scholar
21

Rovea P, Fozza A, Franco P, et al. Once-weekly hypofractionated whole-breast radiotherapy after breast-conserving surgery in older patients: a potential alternative treatment schedule to daily 3-week hypofractionation. Clin Breast Cancer. 2015;15(4):270-276.
Crossref Google Scholar
22

Brunt AM, Wheatley D, Yarnold J, et al. Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Radiother Oncol. 2016;120(1):114-118.
Crossref Google Scholar
23

Murray Brunt A, Haviland JS, Wheatley DA, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward):5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020;395(10237):1613-1626.
Crossref Google Scholar
24

Yarnold J, Bentzen SM, Coles C, Haviland J. Hypofractionated whole-breast radiotherapy for women with early breast cancer: myths and realities. Int J Radiat Oncol Biol Phys. 2011;79(1):1-9.
Crossref Google Scholar
25

Holland R, Veling SH, Mravunac M, Hendriks JH. Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer. 1985;56(5):979-990.
Crossref Google Scholar
26

Njeh CF, Saunders MW, Langton CM. Accelerated partial breast irradiation (APBI):a review of available techniques. Radiat Oncol. 2010;5: 90.
Crossref Google Scholar
27

Kahán Z, Csenki M, Varga Z, et al. The risk of early and late lung sequelae after conformal radiotherapy in breast cancer patients. Int J Radiat Oncol Biol Phys. 2007;68(3):673-681.
Crossref Google Scholar
28

Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987-698.
Crossref Google Scholar
29

van den Bogaard VA, Ta BD, van der Schaaf A, et al. Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures [published correction appears in J Clin Oncol. 2017 Nov 10;35(32):3736]. J Clin Oncol. 2017;35(11):1171-1178.
Crossref Google Scholar
30

Mille MM, Xu XG, Rivard MJ. Comparison of organ doses for patients undergoing balloon brachytherapy of the breast with HDR 192Ir or electronic sources using Monte Carlo simulations in a heterogeneous human phantom. Med Phys. 2010;37(2):662-671.
Crossref Google Scholar
31

Coles CE, Griffin CL, Kirby AM, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial):5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet. 2017;390(10099):1048-1060.
Crossref Google Scholar
32
Royal College of Radiologists. Postoperative radiotherapy for breastcancer: UK consensus statements. 2016;(November). Availablefrom: https://www.rcr.ac.uk/publication/postoperative-radiotherapybreast-cancer-uk-consensus-statements
33

Offersen BV, Alsner J, Nielsen HM, et al. Partial breast irradiation versus whole breast irradiation for early breast cancer patients in a randomized phase III trial: the Danish breast cancer group partial breast irradiation trial. J Clin Oncol. 2022;40(36):4189-4197.
Crossref Google Scholar
34

Formenti SC, Hsu H, Fenton-Kerimian M, et al. Prone accelerated partial breast irradiation after breast-conserving surgery: five-year results of 100 patients. Int J Radiat Oncol Biol Phys. 2012;84(3):606-611.
Crossref Google Scholar
35

Huppert N, Jozsef G, Dewyngaert K, Formenti SC. The role of a prone setup in breast radiation therapy. Front Oncol. 2011;1: 31.
Crossref Google Scholar
36

Vaidya JS, Wenz F, Bulsara M, et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial [published correction appears in Lancet. 2014 Feb 15;383(9917):602]. Lancet. 2014;383(9917):603-613.
Crossref Google Scholar
37

Shah C, Khan AJ, Arthur D, Fernandez E, Martinez AA, Vicini F. Intraoperative radiation therapy in breast cancer: not ready for prime time. Ann Surg Oncol. 2014;21(2):351-353.
Crossref Google Scholar
38

Vaidya JS, Joseph DJ, Tobias JS, et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial):an international, prospective, randomised, non-inferiority phase 3 trial. Lancet. 2010;376(9735):91-102.
Crossref Google Scholar
39

Veronesi U, Orecchia R, Maisonneuve P, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT):a randomised controlled equivalence trial. Lancet Oncol. 2013;14(13):1269-1277.
Crossref Google Scholar
40

Correa C, Harris EE, Leonardi MC, et al. Accelerated partial breast irradiation: update of an ASTRO evidence-based consensus statement. Pract Radiat Oncol. 2017;7(2):73-79.
Crossref Google Scholar
41

Polgár C, Van Limbergen E, Pötter R, et al. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). Radiother Oncol. 2010;94(3):264-273.
Crossref Google Scholar
42

Julian TB, Costantino JP, Vicini FA, et al. Early toxicity results with 3-D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. Int J Radiat Oncol. 2011;81(2):S7.
Crossref Google Scholar
43

Vicini FA, Cecchini RS, White JR, et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet. 2019;394(10215):2155-2164.
Crossref Google Scholar
44

Whelan TJ, Julian JA, Berrang TS, et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID):a randomised controlled trial. Lancet. 2019;394(10215):2165-2172.
Crossref Google Scholar
45

Schäfer R, Strnad V, Polgár C, et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO):5-year results of a randomised, phase 3 trial. Lancet Oncol. 2018;19(6):834-844.
Crossref Google Scholar
46

Strnad V, Ott OJ, Hildebrandt G, et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet. 2016;387(10015):229-238.
Crossref Google Scholar
47

Livi L, Meattini I, Marrazzo L, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer. 2015;51(4):451-463.
Crossref Google Scholar
48

Meattini I, Saieva C, Marrazzo L, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Res Treat. 2015;153(3):539-547.
Crossref Google Scholar
49

Vaidya JS, Bulsara M, Baum M, et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: tARGIT-A randomised clinical trial. BMJ. 2020;370: m2836. Published 2020 Aug 19.
Crossref Google Scholar
50

Orecchia R, Veronesi U, Maisonneuve P, et al. Intraoperative irradiation for early breast cancer (ELIOT):long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial. Lancet Oncol. 2021;22(5):597-608.
Crossref Google Scholar
51

Hepel JT, Tokita M, MacAusland SG, et al. Toxicity of three-dimensional conformal radiotherapy for accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2009;75(5):1290-1296.
Crossref Google Scholar
52
Hickey BE, Lehman M, Francis DP, See AM. Partial breast irradiation for early breast cancer. Cochrane Database Syst Rev. 2016;7(7):CD007077. Published 2016 Jul 18.
Crossref
53

Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070.
Crossref Google Scholar
54

Rahimi A, Thomas K, Spangler A, et al. Preliminary results of a phase 1 dose-escalation trial for early-stage breast cancer using 5-fraction stereotactic body radiation therapy for partial-breast irradiation. Int J Radiat Oncol Biol Phys. 2017;98(1):196-205.
Crossref Google Scholar
55

Bondiau PY, Courdi A, Bahadoran P, et al. Phase 1 clinical trial of stereotactic body radiation therapy concomitant with neoadjuvant chemotherapy for breast cancer. Int J Radiat Oncol Biol Phys. 2013;85(5):1193-1199.
Crossref Google Scholar
56

Yu CX, Shao X, Zhang J, et al. GammaPod-a new device dedicated for stereotactic radiotherapy of breast cancer. Med Phys. 2013;40(5):051703.
Crossref Google Scholar
57

Mutaf YD, Zhang J, Yu CX, et al. Dosimetric and geometric evaluation of a novel stereotactic radiotherapy device for breast cancer: the GammaPod™. Med Phys. 2013;40(4):041722.
Crossref Google Scholar
58

Snider JW, Nichols EM, Mutaf YD, et al. Reproducibility of a novel, vacuum-assisted immobilization for breast stereotactic radiotherapy. J Appl Clin Med Phys. 2021;22(3):8-15.
Crossref Google Scholar
59

Ödén J, Toma-Dasu I, Yu CX, Feigenberg SJ, Regine WF, Mutaf YD. Dosimetric comparison between intra-cavitary breast brachytherapy techniques for accelerated partial breast irradiation and a novel stereotactic radiotherapy device for breast cancer: GammaPod™. Phys Med Biol. 2013;58(13):4409-4421.
Crossref Google Scholar
60

Snider JW, Mutaf Y, Nichols E, et al. Dosimetric improvements with a novel breast stereotactic radiotherapy device for delivery of preoperative partial-breast irradiation. Oncol. 2017;92(1):21-30.
Crossref Google Scholar
61

Snider JW, Mutaf Y, Hall A, et al. Dosimetric improvements based on vacuum assisted breast immobilization utilized with a novel breast stereotactic radiation therapy (BSRT) device. Int J Radiat Oncol Biol Phys. 2015;93(3):E53.
Crossref Google Scholar
62

Becker SJ, Niu Y, Mutaf Y, et al. Development and validation of a comprehensive patient-specific quality assurance program for a novel stereotactic radiation delivery system for breast lesions. J Appl Clin Med Phys. 2019;20(12):138-148.
Crossref Google Scholar
63

Snider J, Mutaf Y, Nichols EM, et al. Preoperative partial breast irradiation with a novel breast- specific stereotactic radiotherapy (BSRT) device: projected improvements in cosmetic outcomes over volumetric modulated arc therapy (VMAT). Cureus J Med Sci. 2016;8(6):a102.
Google Scholar
64

Vermeulen SS, Haas JA. CyberKnife stereotactic body radiotherapy and CyberKnife accelerated partial breast irradiation for the treatment of early breast cancer. Transl Cancer Res. 2014;3(4):295-302.
Google Scholar
65

Obayomi-Davies O, Kole TP, Oppong B, et al. Stereotactic accelerated partial breast irradiation for early-stage breast cancer: rationale, feasibility, and early experience using the CyberKnife radiosurgery delivery platform. Front Oncol. 2016;6: 129.
Crossref Google Scholar
66
University of Maryland Single Fraction Boost (trial ID NCT03562273):https://clinicaltrials.gov/ct2/show/NCT03562273 Title: Tumor BedBoost Using a Breast Specific Radiosurgery Device, The GammaPod™: registry Study and Evaluation of Quality of Life With Development of SizingNomogram.
67
University of Texas South western Medical Center Five FractionS-PBI (trial ID NCT03581136):https://clinicaltrials.gov/show/NCT03581136 Title: Phase II Multi-center Trial Evaluating 5 FractionS-PBI (Stereotactic Partial Breast Irradiation) for Early Stage Breast CancerUsing the GammaPod.
68

Nichols EM, Dhople AA, Mohiuddin MM, Flannery TW, Yu CX, Regine WF. Comparative analysis of the post-lumpectomy target volume versus the use of pre-lumpectomy tumor volume for early-stage breast cancer: implications for the future. Int J Radiat Oncol Biol Phys. 2010;77(1):197-202.
Crossref Google Scholar
69

Van Der Leij F, Elkhuizen PHM, Janssen TM, et al. Target volume delineation in external beam partial breast irradiation: less inter-observer variation with preoperative-compared to postoperative delineation. Radiother Oncol. 2014;110(3):467-470.
Crossref Google Scholar
70

Blitzblau RC, Arya R, Yoo S, et al. A phase 1 trial of preoperative partial breast radiation therapy: patient selection, target delineation, and dose delivery. Pract Radiat Oncol. 2015;5(5):e513-520.
Crossref Google Scholar
71

Van Der Leij F, Bosma SCJ, Van De Vijver MJ, et al. First results of the preoperative accelerated partial breast irradiation (PAPBI) trial. Radiother Oncol. 2015;114(3):322-327.
Crossref Google Scholar
72

Charaghvandi RK, van Asselen B, Philippens MEP, et al. Redefining radiotherapy for early-stage breast cancer with single dose ablative treatment: a study protocol. BMC Cancer. 2017;17(1):181.
Crossref Google Scholar
73
Maisonneuve-Rosemont Hospital SPORT-DS trial: Single PreOperative Radiation Therapy - With Delayed or No Surgery (SPORT-DNS) for Low Risk Breast Cancer: A Phase II Study https://clinicaltrials.gov/ct2/show/NCT05217966
74
Johns Hopkins' SBRT trial: A Phase II Study of Preoperative Single Fraction Stereotactic Body Radiotherapy to the Intact Breast in Early Stage Low Risk Breast Cancer: Analysis of Radiation Response, https://clinicaltrials.gov/ct2/show/NCT03043794
75
Duke University SRS trial: A Phase II Preoperative Single-Fraction Partial Breast Radiotherapy in Early Stage Breast Cancer: Analysis of Pathologic Response, https://clinicaltrials.gov/ct2/show/NCT02482376
76
UTSW Single Fraction Pre-Operative Dose Escalation (trial ID NCT04040569):https://clinicaltrials.gov/ct2/show/NCT04040569 Title: Dose escalation study of single fraction early stage breast cancer.
77
University of Maryland Single Fraction Pre-Operative Dose Escalation (trial ID NCT04234386):https://clinicaltrials.gov/ct2/show/ NCT04234386 Title: Phase Ib Dose Escalation of Single-Fraction Preoperative Stereotactic Partial-Breast Irradiation for Early-Stage BreastCancer.
Precision Radiation Oncology
Volume 7 Issue 1,
March 2023
Pages 67-79
DOI: 10.1002/pro6.1183
Cite this article:
Yu CX. Radiotherapy of early-stage breast cancer. Precision Radiation Oncology, 2023, 7(1): 67-79. https://doi.org/10.1002/pro6.1183

362

Views

3

Crossref

4

Scopus

Altmetrics
Received: 23 November 2022
Revised: 07 December 2022
Accepted: 08 December 2022
Published: 29 January 2023
© 2023 The Authors. Precision Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Shandong Cancer Hospital & Institute.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Return